Lu AA24530 for the treatment of mood and anxiety disorders enters into clinical phase II
H. Lundbeck A/S and Takeda Pharmaceutical Company Limited announced the decision to investigate Lu AA24530 for the treatment of depression in patients. Based on positive, pre-clinical results, as well as the positive conclusion of the phase I trials in healthy individuals, the first patient in a 600 patient phase II study has been enrolled.
Lu AA24530, discovered by Lundbeck, belongs to a new chemical class and represents an approach that is different to currently marketed antidepressants. Lu AA24530 is being jointly developed by Lundbeck and Takeda and is the second most advanced compound in the collaboration on a new class of compounds to treat mood and anxiety disorders.
In September 2007, Lundbeck and Takeda formed an alliance to develop and commercialize a portfolio of novel compounds in the US and Japan for the treatment of mood and anxiety disorders, including Lu AA24530 and Lu AA21004, which is in a more advanced clinical development stage.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.